Neuralstem, a biopharmaceutical company focused on the development of central nervous system therapies based on its neuronal stem cell technology, has appointed Richard Daly as President and Chief Executive.
Daly brings to the position more than 25 years of commercial pharmaceutical leadership experience encompassing strategy, sales, marketing, and operations. He also joins the company's Board of Directors.
Daly succeeds Richard Garr, who has been President and Chief Executive since co-founding Neuralstem with Chairman and Chief Scientific Officer, Karl Johe, in 1996. Garr will continue to be a member of the Board of Directors and will assist in the transition period.
Most recently Daly was Managing Director of Ravine Rock Partners, a healthcare commercial performance acceleration firm where his expertise was leveraged as the Interim Chief Commercial Officer of Catalyst Pharma until September 2015. He also led the turnaround initiatives of Bristol-Myers Squibb – AstraZeneca Diabetes Alliance when serving as President of the US Diabetes subsidiary from 2013 to the AstraZeneca integration completion in 2014.
From 2011 to 2013, Daly was a founding Partner and Board Member of SagePath Partners, a commercial outsourcing provider to the pharmaceutical industry.
He was also part of the executive leadership team that executed the formation and growth of Takeda North America. During his 13-year tenure, he was Executive Vice President, US, where he was responsible for new affiliates and business development for the Americas.
Earlier in his career, he was Vice President of Commercial Strategy at TAP Pharmaceuticals, an Abbott Labs and Takeda joint-venture, and Senior Vice President of Marketing at Takeda North America.
